Identification of S100A8 and S100A9 as serological markers for colorectal cancer

Journal of Proteome Research

Volumn 8, Issue 3, 2009, Pages 1368-1379

  Kim, Hye Jung ^a,b   Kang, Hyun Ju ^c   Lee, Hanna ^c   Lee, Seung Taek ^b   Yu, Myeong Hee ^a   Kim, Hoguen ^c   Lee, Cheolju ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; DIGE; S100A8; S100A9; Serological biomarker

Indexed keywords

ADENOSYLHOMOCYSTEINASE; CALGRANULIN A; CALGRANULIN B; CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; NUCLEOSIDE DIPHOSPHATE KINASE A;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREATITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOSYLHOMOCYSTEINASE; AMINO ACID SEQUENCE; CALGRANULIN A; CALGRANULIN B; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MOLECULAR SEQUENCE DATA; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROTEOME; RNA, MESSENGER; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 65249165399     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr8007573     Document Type: Article

References (66)

1. Bingham, S.; Riboli, E. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat. Rev. Cancer 2004, 4 (3), 206-215.
2. Sung, J. J.; Lau, J. Y.; Goh, K. L.; Leung, W. K. Asia Pacific Working Group on Colorectal Cancer, Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005, 6 (11), 871-876.
3. Hardcastle, J. D.; Chamberlain, J. O.; Robinson, M. H.; Moss, S. M.; Amar, S. S.; Balfour, T. W.; James, P. D.; Mangham, C. M. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348 (9040), 1472-1477.
4. Kronborg, O.; Fenger, C.; Olsen, J.; Jorgensen, O. D.; Sondergaard, O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348 (9040), 1467-1471.
5. Inger, D. B. Colorectal cancer screening. Prim. Care 1999, 26 (1), 179-187.
6. Ahlquist, D. A. Fecal occult blood testing for colorectal cancer. Can we afford to do this? Gastroenterol. Clin. North Am. 1997, 26 (1), 41-55.
7. Collins, J. F.; Lieberman, D. A.; Durbin, T. E.; Weiss, D. G. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann. Intern. Med. 2005, 142 (2), 81-85.
8. Geenen, J. E.; Schmitt, M. G., Jr.; Wu, W. C.; Hogan, W. J. Major complications of coloscopy: bleeding and perforation. Am. J. Dig. Dis. 1975, 20 (3), 231-235.
9. Winawer, S.; Fletcher, R.; Rex, D.; Bond, J.; Burt, R.; Ferrucci, J.; Ganiats, T.; Levin, T.; Woolf, S.; Johnson, D.; Kirk, L.; Litin, S.; Simmang, C. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003, 124 (2), 544-560.
10. Kim, H. J.; Yu, M. H.; Kim, H.; Byun, J.; Lee, C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep. 2008, 41 (10), 685-692.
11. Bast, R. C., Jr.; Ravdin, P.; Hayes, D. F.; Bates, S.; Fritsche, H., Jr.; Jessup, J. M.; Kemeny, N.; Locker, G. Y.; Mennel, R. G.; Somerfield, M. R. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001, 19 (6), 1865-1878.
12. States, D. J.; Omenn, G. S.; Blackwell, T. W.; Fermin, D.; Eng, J.; Speicher, D. W.; Hanash, S. M. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 2006, 24 (3), 333-338.
13. Rai, A. J.; Gelfand, C. A.; Haywood, B. C.; Warunek, D. J.; Yi, J.; Schuchard, M. D.; Mehigh, R. J.; Cockrill, S. L.; Scott, G. B.; Tammen, H.; Schulz-Knappe, P.; Speicher, D. W.; Vitzthum, F.; Haab, B. B.; Siest, G.; Chan, D. W. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5 (13), 3262-3277.
14. Chang, J. W.; Kang, U.-B.; Kim, D. H.; Yi, J. K.; Lee, J. W.; Noh, D.-Y.; Lee, C.; Yu, M.-H. Identification of circulating endorepellin LG3 fragment: Potential use as a serological biomarker for breast cancer. Proteomics Clin. Appl. 2008, 2 (1), 23-32.
15. Ryu, M. J.; Kim, D.; Kang, U. B.; Kim, J.; Shin, H. S.; Lee, C.; Yu, M. H. Proteomic analysis of y-butyrolactone-treated mouse thalamus reveals dysregulated proteins upon absence seizure. J. Neurochem. 2007, 102 (3), 646-656.
16. Kim, H.; Kang, H. J.; You, K. T.; Kim, S. H.; Lee, K. Y.; Kim, T. I.; Kim, C.; Song, S. Y.; Kim, H. J.; Lee, C.; Kim, H. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006, 6 (11), 3466-3476.
17. Chen, Y.; Zhang, Y.; Yin, Y.; Gao, G.; Li, S.; Jiang, Y.; Gu, X.; Luo, J. SPD-a web-based secreted protein database. Nucleic Acids Res. 2005, 33 (Database issue), D169-173.
18. Alfonso, P.; Nunez, A.; Madoz-Gurpide, J.; Lombardia, L.; Sanchez, L.; Casal, J. I. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 2005, 5 (10), 2602-2611.
19. Bi, X.; Lin, Q.; Foo, T. W.; Joshi, S.; You, T.; Shen, H. M.; Ong, C. N.; Cheah, P. Y.; Eu, K. W.; Hew, C. L. Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol. Cell. Proteomics 2006, 5 (6), 1119-1130.
20. Friedman, D. B.; Hill, S.; Keller, J. W.; Merchant, N. B.; Levy, S. E.; Coffey, R. J.; Caprioli, R. M. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4 (3), 793-811.
21. Rodriguez-Pineiro, A. M.; de la Cadena, M. P.; Lopez-Saco, A.; Rodriguez-Berrocal, F. J. Differential expression ofserum clusterin isoforms in colorectal cancer. Mol. Cell. Proteomics 2006, 5 (9), 1647-1657.
22. Roessler, M.; Rollinger, W.; Palme, S.; Hagmann, M. L.; Berndt, P.; Engel, A. M.; Schneidinger, B.; Pfeffer, M.; Andres, H.; Karl, J.; Bodenmuller, H.; Ruschoff, J.; Henkel, T.; Rohr, G.; Rossol, S.; Rosch, W.; Langen, H.; Zolg, W.; Tacke, M. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 2005, 11 (18), 6550-6557.
23. Xing, X.; Lai, M.; Gartner, W.; Xu, E.; Huang, Q.; Li, H.; Chen, G. Identification of differentially expressed proteins in colorectal cancer by proteomics: down-regulation of secretagogin. Proteomics 2006, 6 (9), 2916-2923.
24. Stulik, J.; Hernychova, L.; Porkertova, S.; Knizek, J.; Macela, A.; Bures, J.; Jandik, P.; Langridge, J. I.; Jungblut, P. R. Proteome study of colorectal carcinogenesis. Electrophoresis 2001, 22 (14), 3019-3025.
25. Sagynaliev, E.; Steinert, R.; Nestler, G.; Lippert, H.; Knoch, M.; Reymond, M. A. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 2005, 5 (12), 3066-3078.
26. Melis, R.; White, R. Characterization of colonic polyps by two- dimensional gel electrophoresis. Electrophoresis 1999, 20 (4-5), 1055-1064.
27. Roessler, M.; Rollinger, W.; Mantovani-Endl, L.; Hagmann, M. L.; Palme, S.; Berndt, P.; Engel, A. M.; Pfeffer, M.; Karl, J.; Bodenmuller, H.; Ruschoff, J.; Henkel, T.; Rohr, G.; Rossol, S.; Rosch, W.; Langen, H.; Zolg, W.; Tacke, M. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry- based approach for data analysis. Mol. Cell. Proteomics 2006, 5 (11), 2092-2101.
28. Tomonaga, T.; Matsushita, K.; Yamaguchi, S.; Oh-Ishi, M.; Kodera, Y.; Maeda, T.; Shimada, H.; Ochiai, T.; Nomura, F. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res. 2004, 10 (6), 2007-2014.
29. Indinnimeo, M.; Giarnieri, E.; Stazi, A.; Cicchini, C.; Brozzetti, S.; Valli, C.; Carreca, I.; Vecchione, A. Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression. Cancer Lett. 1997, 111 (1-2), 1-5.
30. Tannapfel, A.; Katalinic, A.; Kockerling, F.; Wittekind, C. The prediction of lymph node metastases in colorectal cancer by expression of the nucleoside diphosphate kinase/nm23-H1 and histopathological variables. Am. L Gastroenterol 1997, 92 (7), 1182-1186.
31. Fan, Z.; Beresford, P. J.; Oh, D. Y.; Zhang, D.; Lieberman, J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003, 112 (5), 659-672.
32. Lombardi, D.; Lacombe, M. L.; Paggi, M. G. nm23: unraveling its biological function in cell differentiation. J. Cell. Physiol. 2000, 182 (2), 144-149.
33. Aryee, D. N.; Simonitsch, I.; Mosberger, I.; Kos, K.; Mann, G.; Schlogl, E.; Potschger, U.; Gadner, H.; Radaszkiewicz, T.; Kovar, H. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness. Br. J. Cancer 1996, 74 (11), 1693-1698.
34. Niitsu, N.; Okamoto, M.; Honma, Y.; Nakamine, H.; Tamaru, J. I.; Nakamura, S.; Yoshino, T.; Higashihara, M.; Hirano, M.; Okabe- Kado, J. Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphoma. Leukemia 2003, 17 (5), 987-990.
35. Brenner, A. S.; Thebo, J. S.; Senagore, A. J.; Duepree, H. J.; Gramlich, T.; Ormsby, A.; Lavery, I. C.; Fazio, V. W. Analysis of both NM23- h1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer. Am. Surg. 2003, 69 (3), 203-208.
36. Dursun, A.; Akyurek, N.; Gunel, N.; Yamac, D. Prognostic implication of nm23-H1 expression in colorectal carcinomas. Pathology 2002, 34 (5), 427-432.
37. Forte, A.; D'Urso, A.; Gallinaro, L. S.; Lo Storto, G.; Soda, G.; Bosco, D.; Bezzi, M.; Vietri, F.; Beltrami, V. NM23 expression as prognostic factor in colorectal carcinoma. G. Chir. 2002, 23 (3), 61-63.
38. Heys, S. D.; Langlois, N.; Smith, I. C.; Walker, L. G.; Eremin, O. NM23 gene product expression does not predict lymph node metastases or survival in young patients with colorectal cancer. Oncol. Rep. 1998, 5 (3), 735-739.
39. Lindmark, G. NM-23 H1 immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer. Br. J. Cancer 1996, 74 (9), 1413-1418.
40. Turner, M. A.; Yang, X.; Yin, D.; Kuczera, K.; Borchardt, R. T.; Howell, P. L. Structure and function of S-adenosylhomocysteine hydrolase. Cell Biochem. Biophys. 2000, 33 (2), 101-125.
41. Peters, D. G.; Kudla, D. M.; Deloia, J. A.; Chu, T. J.; Fairfull, L.; Edwards, R. P.; Ferrell, R. E. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol. Biomarkers Prev. 2005, 14 (7), 1717-1723.
42. De Angelis, P. M.; Svendsrud, D. H.; Kravik, K. L.; Stokke, T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol. Cancer 2006, 5, 20.
43. El-Rifai, W.; Moskaluk, C. A.; Abdrabbo, M. K.; Harper, J.; Yoshida, C.; Riggins, G. J.; Frierson, H. F., Jr.; Powell, S. M. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002, 62 (23), 6823-6826.
44. Hermani, A.; Hess, J.; De Servi, B.; Medunjanin, S.; Grobholz, R.; Trojan, L.; Angel, P.; Mayer, D. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 2005, 11 (14), 5146-5152.
45. Cross, S. S.; Hamdy, F. C.; Deloulme, J. C.; Rehman, I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005, 46 (3), 256-269.
46. Arai, K.; Teratani, T.; Nozawa, R.; Yamada, T. Immunohistochemi- cal investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol. Rep. 2001, 8 (3), 591-596.
47. Arai, K.; Yamada, T.; Nozawa, R. Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med. Oncol. 2000, 17 (3), 183-188.
48. Sheikh, A. A.; Vimalachandran, D.; Thompson, C. C.; Jenkins, R. E.; Nedjadi, T.; Shekouh, A.; Campbell, F.; Dodson, A.; Prime, W.; Crnogorac-Jurcevic, T.; Lemoine, N. R.; Costello, E. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics 2007, 7 (11), 1929-1940.
49. Nacken, W.; Roth, J.; Sorg, C.; Kerkhoff, C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc. Res. Tech. 2003, 60 (6), 569-580.
50. Odink, K.; Cerletti, N.; Bruggen, J.; Clerc, R. G.; Tarcsay, L.; Zwadlo, G.; Gerhards, G.; Schlegel, R.; Sorg, C. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987, 330 (6143), 80-82.
51. Striz, I.; Trebichavsky, I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol. Res. 2004, 53 (3), 245-253.
52. Ryckman, C.; Gilbert, C.; de Medicis, R.; Lussier, A.; Vandal, K.; Tessier, P. A. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J. Leukocyte Biol. 2004, 76 (2), 433-440.
53. Ryckman, C.; Vandal, K.; Rouleau, P.; Talbot, M.; Tessier, P. A. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J. Immunol. 2003, 170 (6), 3233-3242.
54. Takemoto, N.; Konishi, F.; Yamashita, K.; Kojima, M.; Furukawa, T.; Miyakura, Y.; Shitoh, K.; Nagai, H. The correlation of micro- satellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. Jpn. J. Clin. Oncol. 2004, 34 (2), 90-98.
55. Ropponen, K. M.; Eskelinen, M. J.; Lipponen, P. K.; Alhava, E.; Kosma, V. M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 1997, 182 (3), 318-324.
56. Johne, B.; Kronborg, O.; Ton, H. I.; Kristinsson, J.; Fuglerud, P. A new fecal calprotectin test for colorectal neoplasia. Scand. J. Gastroenterol. 2001, 36 (3), 291-296.
57. Kristinsson, J.; Armbruster, C. H.; Ugstad, M.; Kriwanek, S.; Nygaard, K.; Ton, H.; Fuglerud, P. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand. J. Gastroenterol. 2001, 36 (2), 202-207.
58. Kronborg, O.; Ugstad, M.; Fuglerud, P.; Johne, B.; Hardcastle, J.; Scholefield, J. H.; Vellacott, K.; Moshakis, V.; Reynolds, J. R. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000, 46 (6), 795-800.
59. Poullis, A.; Foster, R.; Shetty, A.; Fagerhol, M. K.; Mendall, M. A. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2004, 13 (2), 279-284.
60. Roseth, A. G.; Kristinsson, J.; Fagerhol, M. K.; Schjonsby, H.; Aadland, E.; Nygaard, K.; Roald, B. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand. J. Gastroenterol. 1993, 28 (12), 1073-1076.
61. Tibble, J.; Sigthorsson, G.; Foster, R.; Sherwood, R.; Fagerhol, M.; Bjarnason, I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001, 49 (3), 402-408.
62. Damms, A.; Bischoff, S. C. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int. J. Colorectal Dis. 2008, 23 (10), 985-992.
63. Husebye, E.; Ton, H.; Johne, B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am. J. Gastroenterol. 2001, 96 (9), 2683-2687.
64. Limburg, P. J.; Devens, M. E.; Harrington, J. J.; Diehl, N. N.; Mahoney, D. W.; Ahlquist, D. A. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am. J. Gastroenterol. 2003, 98 (10), 2299-2305.
65. Mor, G.; Visintin, I.; Lai, Y.; Zhao, H.; Schwartz, P.; Rutherford, T.; Yue, L.; Bray-Ward, P.; Ward, D. C. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (21), 7677-7682.
66. Duffy, M. J.; van Dalen, A.; Haglund, C.; Hansson, L.; Holinski- Feder, E.; Klapdor, R.; Lamerz, R.; Peltomaki, P.; Sturgeon, C.; Topolcan, O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 2007, 43 (9), 1348-1360.